QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

@article{Evans2001QS21PA,
  title={QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.},
  author={Thomas G. Evans and M. Julie Mcelrath and Thomas J. Matthews and David C. Montefiori and Kent J. Weinhold and Mark C. Wolff and Michael C. Keefer and Esper G. Kallas and Lawrence Corey and Geoffrey J Gorse and Robert B Belshe and Barney S. Graham and Paul Spearman and David H. Schwartz and Mark J Mulligan and Paul A Goepfert and Patricia E Fast and Phillip W Berman and Michael F. Powell and Donald Francis},
  journal={Vaccine},
  year={2001},
  volume={19 15-16},
  pages={
          2080-91
        }
}
Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1(MN) protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 microg), either alone or in combination with aluminum hydroxide (600 microg). At the highest doses of rsgp120 (100, 300, and 600 microg), QS-21 exerted no significant effect on either binding or neutralizing… Expand
Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing
TLDR
The suitability of reduced dose of QS-21 and the antigen using the Nanopatch to enhance humoral responses, and the potential to increase patient acceptability of Q S-21 adjuvant are demonstrated. Expand
HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
TLDR
Results highlight the potential use of orally administered Talabostat for efficient protein boosting of antibody and T-cell responses primed by DNA. Expand
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
TLDR
Despite the lack of primary isolate neutralizing antibody induction, the observed high frequency and magnitude of other immune responses warrant further work with this vaccine or vaccine components. Expand
Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation
TLDR
This thesis research studied the effects of several adjuvants, QS-21, aluminum hydroxide, MPL, and ISCOMATRIXTM adjuvant in the context of a previously described pentavalent HIV-1 Env DNA prime-protein boost vaccine, DP6-001, and examined the impact of several innate signaling pathways on the adaptive immunity raised by DP 6-001 and adjuants, as well as on the unique serum cytokine profiles. Expand
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
TLDR
The Adjuvant Systems containing MPL/QS21, in combination with hepatitis B surface antigen, induced very strong humoral and cellular immune responses in healthy adults and can be fundamental to develop effective prophylactic vaccines against complex pathogens, e.g. malaria, HIV infection and tuberculosis. Expand
The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.
TLDR
Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine. Expand
Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy
TLDR
The data revealed that the candidate adjuvants in the context of the DP6-001 formulation are characterized by unique serum cytokine and chemokine profiles, which will provide valuable guidance in the selection of an adjuvant for future AIDS vaccine development, with the ultimate goal of enhancing immunogenicity while minimizing reactogenicity associated with the use of anAdjuvant. Expand
Instructions for use Title Elicitation of Both Anti HIV-1 Env Humoral and Cellular Immunities by Replicating Vaccinia PrimeSendai Virus Boost Regimen and Boosting by CD 40 Lm Author ( s )
For protection from HIV-1 infection, a vaccine should elicit both humoral and cell-mediated immune responses. A novel vaccine regimen and adjuvant that induce high levels of HIV-1 Env-specific T cellExpand
Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine
TLDR
Most interestingly, DNA prime immunizations made ISCOMATRIX™ adjuvant less dependent on the central innate immune adaptor MyD88, revealing a previously unknown mechanism that may expand knowledge on the use of adjuvants. Expand
Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.
TLDR
It is demonstrated that a novel polyvalent DNA prime/protein boost vaccine lacks signs of toxicity and DNA integration in a rabbit model, and immunogenicity and toxicology data support clinical testing of the vaccine in humans. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
TLDR
These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested, including accelerated the production of antibodies and elicited complete seroconversion after a single immunization, enabling a more economical use of antigen. Expand
Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.
TLDR
Data demonstrated that the QS-21 adjuvant augmented both antibody responses and cell-mediated immunity and established immunological memory and suggest that this adjuant should be safe and effective for use in HIV-1 vaccines. Expand
Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
TLDR
Data demonstrate that CTL capable of recognizing different HIV-1 variants, which are presumed to be specific for a conserved HIV- 1 gp120 epitope, can be induced using subunit vaccines with the appropriate adjuvant while variant-specific antibody responses are produced. Expand
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
TLDR
The ability of QS-21 to augment both antibody and cell-mediated immune responses suggests that this adjuvant could be a valuable component in subunit vaccines. Expand
The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
TLDR
3D-MPL appears to act as an adjuvant, without the toxicity associated with LPS, by controlled and selective potentiating effects on antigen presentation and T-cell activation. Expand
Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
TLDR
In conclusion, the results suggest that formulation with F/QS-21 alters the qualitative and quantitative nature of the immune response to the F glycoprotein when compared with the traditional aluminium-based adjuvants. Expand
Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
TLDR
A concentrated effort has been made to resolve the vaccine-versus-assay issue by focusing mainly on the assay, and it is increasingly clear that the dichotomy in neutralization sensitivity between TCLA strains and primary isolates is unrelated to the assay and actually reflects fundamental differences in the structure of the oligomeric envelope glycoproteins of these two categories of virus. Expand
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
TLDR
Data indicate a restriction of the immune response to linear, conserved epitopes poorly accessible on both monomeric and cell-surface expressed oligomeric gp120/gp41 and a lack of Abs specific for conformational epitopes conserved across divergent HIV-1 strains. Expand
Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1
TLDR
Evaluating the safety and immunogenicity of the MN strain of recombinant gp 120 as a vaccine prototype to prevent human immunodeficiency virus (HIV) found it safe and immunogenic. Expand
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
TLDR
In conclusion, the envelope-based recombinant or synthetic candidate HIV-1 vaccines appear to be safe and this work has prepared the way for the testing of increasingly complex candidate AIDS Vaccine Evaluation Group vaccines. Expand
...
1
2
3
4
5
...